Randomised clinical trial: the effectiveness of Gaviscon Advance vs non‐alginate antacid in suppression of acid pocket and post‐prandial reflux in obese individuals after late‐night supper

Abstract

Background: Late-night supper increases the risk of postprandial reflux from the acid pocket especially in obesity. An alginate-based, raft-forming medication may be useful for obese patients with GERD. Aims: To compare the efficacy of Gaviscon Advance (Reckitt Benckiser, UK) and a non-alginate antacid in post-supper suppression of the acid pocket and post-prandial reflux among obese participants. Methods: Participants underwent 48 h wireless and probe-based pH-metry recording of the acid pocket and lower oesophagus, respectively, and were randomised to single post-supper (10 pm) dose of either Gaviscon Advance or a non-alginate antacid on the second night. Primary outcomes were suppression of median pH of acid pocket and lower oesophagus, measured every 10-minutes post-supper for 1 h. Secondary outcomes were suppression of % time pH < 4 at lower oesophagus and improvement in frequency and visual analogue score (VAS) of regurgitation.Results: Of the 81 screened participants, 55 were excluded and 26 (mean age 33.5 years, males 77.8% and BMI 32.8 kg/m 2 ) were randomised to Gaviscon Advance (n = 13) or antacid (n = 13). Median pH of the acid pocket but not the lower oesophagus was suppressed with Gaviscon Advance vs antacid (all P < 0.04) Gaviscon Advance but not antacid significantly reduced in % time pH < 4, symptom frequency and VAS on day 2 vs day 1 (all P < 0.05). Conclusions: Among obese individuals, Gaviscon Advance was superior to a nonalginate antacid in post-supper suppression of the acid pocket. (Clinical trial registration unique identifier: NCT03516188). | 1015 DERAMAN Et Al.

Connected healthcare: Improving patient care using digital health technologies

“…Known as the PillCam™, the 11 mm x 32 mm device captures images of the colonic lumen with dual cameras, which are transmitted to a sensor array and recorded for physician assessment [29]. Other ingestible sensors have been developed to monitor core body temperature [30][31][32][33][34][35] and gastrointestinal pH [36][37][38][39].…”

Survey-Based Analysis of Current Trends for Prescribing Gastrointestinal Protectants among Small-Animal General Practitioners in Portugal

“…Even though the beneficial effects of antacids (e.g., salts of aluminum hydroxide, calcium carbonate, and magnesium hydroxide) are related to their capacity to raise gastric pH, this action is limited on account of insufficient buffering capacity [ 12 ]. Antacid formulations containing sodium alginate have proven to more effectively control esophageal reflux in people [ 13 , 14 ] as they are thought to displace and/or neutralize the post-prandial acid pocket [ 12 , 13 , 14 ]. However, there is no evidence base to support the use of antacids to treat gastrointestinal ulceration and erosion (GUE) or gastroesophageal reflux (GER) disease in dogs and cats [ 12 ].…”

Consensus statements and recommendations on the management of mild‐to‐moderate gastroesophageal reflux disease in the Southeast Asian region

“…Alginate‐based formulation was comparable to omeprazole in achieving a heartburn‐free period in patients with moderate episodic heartburn and is a promising alternative treatment for moderate GERD 76 . In the most recent randomized clinical trial, an alginate‐containing product has been shown to be superior to antacid in post‐supper suppression of the acid pocket in obese individuals 77 78 …”